AzTrials
AzTrials

Periodontal DiseasesNCT06993818

Asprosın And Tumor Necrosıs Factor-α Levels In Type 2 Dıabetıc Chronıc Periodontitis

An observational study of Periodontal Diseases, run by Eda Cetin Ozdemir at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Periodontal disease is a chronic, multifactorial inflammatory disease in which biochemical and cellular events trigger each other, leading to the destruction of the tissues supporting the teeth . Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Periodontal Diseases
What is being tested?
Gingival Crevicular Fluid and Serum Asprosin
How many people
102 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Nov 2024to 15 Apr 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients applying to Kahramanmaraş Sütçü İmam University, Faculty of Dentisrty, Department of Periodontology.

Who may be able to join

  • The patient must be a volunteer

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Kahramanmaraş Sütçü İmam University

    Kahramanmaraş

Other trials in Turkey (Türkiye)

About this study

Official title: Evaluatıon Of Asprosın And Tumor Necrosıs Factor-α Levels In Gıngıval Crevıcular Fluıd And Serum Of Patıents Wıth Controlled And Uncontrolled Type 2 Dıabetıc Chronic Periodontitis

Periodontal disease is a chronic, multifactorial inflammatory disease in which biochemical and cellular events trigger each other, leading to the destruction of the tissues supporting the teeth . The pathogenesis of the disease is a dynamic process that develops as a result of complex interactions between pathogenic bacteria and the host response . There is a bidirectional relationship between diabetes mellitus (DM), which is among the systemic diseases that negatively affect the host immune response, and periodontal disease. In the case of DM, long-term hyperglycemia causes proteins to react irreversibly with glucose, resulting in the formation of advanced glycation end products (AGEs). It is suggested that increased AGE levels increase cytokine secretion against periodontopathogens, exacerbate inflammatory tissue destruction, and may negatively affect biological functions through cell-cell and cell-matrix interactions in the connective tissue.

The present study was conducted to gain further insight into the role of CGF and serum Asprosin level in the pathogenetic processes linking DM and periodontal disease.

Read the detailed description

Periodontal disease is a chronic, multifactorial inflammatory disease in which biochemical and cellular events trigger each other, leading to the destruction of the tissues supporting the teeth . The pathogenesis of the disease is a dynamic process that develops as a result of complex interactions between pathogenic bacteria and the host response . There is a bidirectional relationship between diabetes mellitus (DM), which is among the systemic diseases that negatively affect the host immune response, and periodontal disease . In the case of DM, long-term hyperglycemia causes proteins to react irreversibly with glucose, resulting in the formation of advanced glycation end products (AGEs). It is suggested that increased AGE levels increase cytokine secretion against periodontopathogens, exacerbate inflammatory tissue destruction, and may negatively affect biological functions through cell-cell and cell-matrix interactions in the connective tissue . Periodontitis, a widespread infectious disease, is also considered a systemic inflammation. In the presence of periodontitis, some inflammatory cytokines are produced in periodontal tissues and their levels in the circulation also increase . It has been reported that the levels of Tumor necrosis factor-α (TNF-α), which is considered an acute phase reactant, are increased in the adipose tissue of diabetic rodents. TNF-α has proinflammatory properties and can reduce insulin sensitivity . Studies have shown that diabetic monocytes secrete 24-32 times more TNF-α; this situation is associated with the development and progression of diabetic periodontitis. Adipokines are important molecules secreted from adipose tissue and play a role in various physiological processes such as energy intake, blood pressure, metabolism and inflammation . In 2016, Romere et al. showed that plasma levels of Asprosin, encoded by the Fibrillin-1 gene, increase in the fasting state and decrease after meals. After crossing the blood-brain barrier, the asprosin hormone stimulates the orexigenic (appetite-increasing) AgRP neuron group through a cAMP-dependent pathway activity. Simultaneously, gamma aminobutyric acid-dependent proopiomelanocortin neurons are suppressed, thus increasing appetite, obesity, and ultimately body weight . Asprosin is associated with diseases such as diabetes mellitus, obesity, polycystic ovary syndrome, and cardiovascular diseases . Recent studies have shown that asprosin plays a role in the inflammatory responses of many cell types. Asprosin increases B cell-dependent inflammation by inducing hepatic glucose synthesis and also increases blood glucose levels by inhibiting insulin secretion . Many studies have shown that serum asprosin concentrations in patients with type 2 diabetes mellitus are systemically higher than in healthy controls . However, the authors did not find any studies in the literature evaluating asprosin levels in individuals with type 2 DM and chronic periodontitis. In light of the previous studies summarized above, the present study was conducted to gain more insight into the role of CGF and serum Asprosin levels in the pathogenetic processes linking DM and periodontal disease. This study is the first to examine Asprosin levels in gingival crevicular fluid (GCF) and serum of CP patients with T2DM.

Being tested
Gingival Crevicular Fluid, Serum Asprosin
Keywords
Periodontitis, Diabetes Mellitus, Asprosin levels
Medical subject headings
Periodontal Diseases, Periodontitis, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Gingival Crevicular FluidOther

    Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples

  • Serum AsprosinDiagnostic test

    Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples

Study groups in NCT06993818
Study groupRoleWhat they receive
Control Group: systemically and periodontally healthy control groupPeriodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
Receives: Other: Gingival Crevicular Fluid; Diagnostic Test: Serum Asprosin
Uncontrolled T2DM-CP: Stage III Grade C Periodontitis, Uncontrolled T2DM groupPeriodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
Receives: Other: Gingival Crevicular Fluid; Diagnostic Test: Serum Asprosin
Controlled T2DM-CP: Stage III Grade B Periodontitis, Controlled T2DMPeriodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
Receives: Other: Gingival Crevicular Fluid; Diagnostic Test: Serum Asprosin
CP: Stage III Grade B Periodontitis groupPeriodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
Receives: Other: Gingival Crevicular Fluid; Diagnostic Test: Serum Asprosin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in Asprosin Levels in GCF an Serum Samples in periodontal disease

    Investigators expect a statistically significant difference between controlled and uncontrolled T2DM and CP patients and healthy individuals in terms of serum and CGF Asprosin levels.

    Measured: 6 Mounth

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 May 2025
  2. Study start1 Nov 2024
  3. Primary completion1 Apr 2025
  4. Study completion15 Apr 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
102 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06993818
Sponsor's protocol ID
Kahramanmaraş Sütçü İmam Unive
Status last verified
May 2025
First submitted
13 May 2025
Last updated
29 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: I dont want to share

Questions about this trial

What is this clinical trial studying?

An observational study of Periodontal Diseases, run by Eda Cetin Ozdemir at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in Asprosin Levels in GCF an Serum Samples in periodontal disease (time frame: 6 Mounth). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in